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Abstract  The consequences of bone traumatisation, loss or damage, resulting from injury or disease can dramatically 
reduce the quality of life for a patient at a  significant socioeconomic cost. The aim of bone tissue engineering is not only to 
repair, but also to init iate natural bone regeneration. The u ltimate goal is to develop a synthetic tissue scaffold that uses 
biocompatible materials to produce an effective functional replacement for damaged bone tissue. Thus, avoiding all the 
problems associated with current bone transplantation procedures. However, repairing and regenerating damaged bone 
tissue is still a challenging task. Since the skeletal tissues are complex and the presence of foreign  materials used to 
construct a tissue scaffold within the body’s environment will initiate an inflammatory response, which ultimately leads to 
failure of the repair procedure. This review discusses a number of materials currently being used or has the potential to be 
used in bone tissue engineering applications. In particu lar, the advantages and limitations of hydroxyapatite are discussed at 
length, since its desirable properties such as biocompatibility, b ioactivity, osteoconductivity and osteoinductivity make it an 
ideal starting material for bone tissue engineering applications. 
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1. Introduction 
Today, there is a high demand for advanced biosynthetic 
bone-like materials for the development o f b iomedical 
devices and implants for use in tissue engineering 
applications. For example, t issue loss as a result of injury 
and diseases in an increasingly ag ing population reduces the 
quality of life for many at a significant socioeconomic cost. 
This is compounded by the fact that many conventional 
implants fail due to non-integration with the surrounding 
normal tissue. This leads to complications that require 
revision surgery to remove or repair the implant device. 
Furthermore, problems also exist for biomedical devices 
implanted within the body for the controlled release of 
drugs and similar clinical applications. Hence there is an all 
round interest to develop novel tissue engineering 
applications that incorporate “living” constructional 
materials that are similar to natural bone tissue and posses 
the potential to integrate with the surrounding native tissue 
for a faster healing outcome. 
Convent ional medical p rocedures such as autograft  
(patient’s own bone) and allograft, (sourced from another 
donor) treatments for the rep lacement of bone loss resulting  
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from damage or disease have met with varying degrees of 
success to date. Both procedures have significant risks 
associated with them. In the case of an autograft, donor site 
morb idity is a frequent outcome[1, 2], while disease 
transmission is potentially  a serious side effect of an 
allograft  procedure[3]. Furthermore, both procedures suffer 
from the limited supply of viable bone tissue. An attractive 
alternative to nature bone grafts is the use of tissue 
engineering techniques to create synthetic scaffolds that can 
effectively replicate the various physical, chemical and 
mechanical properties found in natural bone tissue. 
There has been considerable development over the past 
few decades in multidiscip linary  field of tissue engineering, 
which has being able to produced engineered implantable 
human tissues such as bone, cartilage and skin[4, 5]. The 
research to date has clearly demonstrated that a major 
function of tissue engineering is to create an environment 
that can promote productive and efficient cellu lar act ivity 
for regenerative purposes. Therefore, it is very important 
that any potential tissue scaffold be capable of replicating 
the extracellular matrix (ECM) and solicits favourable cell 
responses. From the cellular perspective, the interaction 
between the cell and nanometre scale structures is crucial 
for controlling  a variety of cell functions such as adhesion 
and proliferation[6]. 
The operational demands placed on an engineered 
biomedical device or t issue scaffold are numerous and 
presents many challenges that must be overcome to achieve 
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a successful clinical outcome. For example, the biological 
compatibility of the device or scaffold material is crucial in 
preventing any cytotoxicity, immunological reactions, and 
inflammat ion responses from the body[7–9]. The presence 
of any foreign material within  the body environment will 
initiate an immediate inflammatory response at the site. As 
a consequence, a complex biochemical cascade of events 
takes place in which cells arrive and start producing 
chemokines, cytokines and growth factors to init iate the 
repair o f damaged tissues surrounding the foreign material. 
When a scaffold is implanted into the body environment, 
the presence of these cells on the surface of the scaffold can 
initiate a foreign body reaction to the biomaterial used to 
manufacture the scaffold. These cells produce oxygen 
radicals and enzymes that have the potential to degrade the 
scaffold, which can u ltimately lead to the failure o f the 
scaffold[10].  
Historically, a variety of different metals, ceramics and 
polymers have been used to repair or replace damaged bone 
tissue with varying degrees of success. Despite having a 
wide selection of biomaterials and surgical implants, no 
single material to date can exactly match the composition, 
structure, chemical and physical properties of any part icular 
body part. This is especially  true of bone tissue, with its 
very complex h ierarchical structure and its associated 
biological functions such as providing a natural reservoir of 
healing cells and mineral ions that play an important part in 
maintaining the biochemical balance within the body[11, 
12]. 
Since the first total hip  replacement in 1970 by 
Hamadouche et al, based on ceramic alumina, the use of hip 
and knee replacements has steadily increased worldwide 
[13]. Recently, the Australian Orthopaedic Association’s 
National Jo int Replacement Registry noted that there are 
more than 75,000 hip  and knee replacements being carried 
out annually. The register also indicated that there was an 
increasing trend of around 8% per annum in surgical 
procedures involving implant replacements. This trend was 
also reflected in the aging population statistics and also in 
the increasing number of implants and biomedical devices 
being used in younger patients[14]. This health issue is not 
unique to Australia, but in fact is a major g lobal health 
problem facing the world today. And due to its global 
importance, the United Nat ions, the World Health 
Organization and 37 countries declared the period from 
2000 to 2010 as the Bone and Joint Decade[15]. 
For the last 40 years, several approaches have been 
employed to develop biosynthetic bone grafting substitutes 
for the reconstruction of osseous defects[16, 17]. These 
procedures offer patients restored mobility and long-term 
pain relief. However, it should be mentioned that the 
biomaterials used to manufacture the biomedical device or 
implant will have to operate in an environment that is both 
chemically hostile and at the same time very sensitive to the 
presence of foreign materials. Conventional metallic 
materials (316 stainless steel, cobalt chromium and titanium 
alloys) used for hip  and knee replacements, unfortunately 
can fail due to an incompatibility between the modulus of 
elasticity of the orthopaedic implant and the surrounding 
bone tissue (stress shielding)[18]. They also fail due to low 
wear, corrosion resistance and lack of biocompatibility. 
There are currently considerable clinical concerns regarding 
the known toxicities associated with elements in metal 
implants and known pathologies such as particle induced 
inflammat ion (part icles coming from wear debris) and 
hypersensitivity associated with metal implants degradation. 
The body tissues are extremely sensitive to the presence 
foreign part icles and materials, which solicit  an immune 
response that ultimately result’s in the rejection of the 
foreign particles[19]. Despite a new generation of Ti 
implants and a closer elastic modulus to that of natural bone, 
the resulting wear resistance under normal loading 
conditions is still poor[20]. 
Alternative materials such as polymers and ceramics 
have also been investigated for possible use in  a wide range 
of tissue engineering applications. Polymers are large 
molecules composed of smaller repeating structural units 
called monomers. These high purity monomers are usually 
attached by covalent chemical bonds, with cross-linking 
taking place along the length of the macromolecule. It is the 
amount of cross-linking that gives the polymer its 
physiochemical properties. There are many methods of 
producing polymer materials, but electro-spinning is one of 
the most effective processes used for producing nanometre 
sized fibres which  can then be woven into a variety of 
components[21]. Polymers have been used in a variety of 
applications ranging from bone and dental cements, bone 
grafting materials, plates and fixation devices to load 
bearing applications in orthopaedics[22]. In addit ion to 
polymers, several other b iosynthetic ceramic based bone 
substitutes have been developed[23-27]; however, to be 
acceptable, the material should have a high porosity and 
exhibit good mechanical properties, otherwise 
osteoconductivity and resorption at the implant site will be 
affected by the body’s immunological responses[28].  
There has also been considerable research work into 
combin ing materials with desirable propert ies, while at the 
same time trying to avoid some of their less attractive 
properties. The combination of two or more materials for 
their favourable propert ies creates a new composite material 
with a set of unique properties that each individual 
components or phases do not possess. For example, bone is 
a natural two phase organic-inorganic ceramic composite 
composed of collagen fibrils forming one phase, with a well 
embedded array  of inorganic nano-crystalline components 
forming the second phase[29]. Recently, a b iosynthetic 
bone grafting composite material based on nanometre sized 
hydroxyapatite (nano-HAP) and silica were evaluated by 
Gerike et al and Gotz et al, and shown to exhib it good 
osteoinductivity[30, 31]. However, the biosynthetic bone 
graft granules had agglomerated HAP crystals attached to 
their surface. To fu lly benefit from the intrinsic 
physiochemical properties of nano-HAP that originates 
from its large surface area, it is necessary that the 
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nano-HAP crystals are completely d ispersed and are 
individually anchored to the underlying matrix of the 
composite. This problem h ighlights the need for careful 
preparation and efficient manufacture of the composite to 
take full advantage of the respective phases when forming 
the new composite biomaterial potential t issue engineering 
applications. 
2. Bone 
The skeletal system of the human body is important for 
two main reasons; the first is the structural support of the 
organs and other related tissues, the second is related to the 
attachment of muscle groups that permits the motion of the 
body. The skeleton is constructed of a hard natural t issue 
called  bone and cartilaginous materials. The adult human 
skeleton consists of some 206 bones[32];  some of these 
provide protection to the internal organs of the body from 
external forces, while others do specialized functions such 
as the inner ear bones that transmit sound vibrations for the 
sense of hearing. The bone matrix also provides a natural 
reservoir of healing cells and mineral ions that play an 
important part in maintaining the biochemical balance 
within  the body. For example, the calcium level in  the body 
is closely monitored and regulated (in a process called 
homeostasis) since calcium is an important element 
involved in muscular action and nerve conduction[11]. 
2.1. Bone Formation 
Bone format ion (osteogenesis) commences as early as the 
foetal stage and continues throughout adulthood. During 
this period the softer bones of the infant slowly increase in 
hardness during childhood, eventually becoming quite hard 
by the adult stage. This hardening process or ossification is 
the result of the initial hyaline cartilage being transformed 
into bone. There are two methods in which ossificat ion can 
take place, the first is by intramembranous and the second is 
endochondral. Both methods produce bone tissue by 
replacing existing cartilage; however the mechanism that is 
used in each case is quite d ifferent[33]. Intramembranous 
ossification occurs during the formation of the craniofacial 
bones in which mesenchymal cells instead of cartilage are 
transformed direct ly into osteoblasts. In the remainder of 
the body endochondral ossification takes place and begins 
in the embryonic stage with mesenchymal cells forming a 
cartilage matrix. In the following stage, osteoblasts and 
osetoclasts attach themselves to the cartilage matrix. During 
this stage the osteoclasts generate an acidic 
microenvironment that degrades the cartilage, while the 
osteoblasts build a bone matrix onto the cartilage, which 
now forms a scaffold structure[12, 34]. 
2.2. Bone: Its Hierarchical Structure and Mechanical 
Properties 
The structural architecture of bone is h ierarch ical and 
complex[35]. It is an irregular composite material with 
various combinations, arrangements and orientations of its 
component materials at various scales that gives bone its 
heterogeneous and anisotropic nature[36]. The overall 
structure of bone makes it a remarkable b iomaterial with 
unique physical and mechanical properties. For example, 
the toughness of bone is achieved by the interplay of the 
organic collagen scaffold that supports the inorganic 
mineral phase[37, 38]. 
The hierarch ical structural of bone consists of five size 
scales as shown in Figure 1. The first scale is the largest and 
is called the macrostructure, which consists of cortical and 
cancellous bone; the second is the microstructure, which 
ranges in size from 10 to 500 µm and consists of single 
trabeculae or osteons[35]. The oseteon or Haversian system 
consists of cylindrical structures composed of concentric 
layers or lamellae surrounding a central duct called the 
Haversian canal. This canal delivers the blood supply and 
provides connection for the nerves in surrounding bone 
tissue[39]. The next step down in size brings us to the 
sub-microstructure scale, which ranges from 1 to10 µm and 
contains the lamellae which are thin plate like structures 
that form the basic structural unit of the bone in the 
sub-microstructure. The fourth scale is the nanostructure, 
which ranges in size from around 500 nm up to 1µm and 
contains collagen fibre assemblies composed predominantly 
of collagen fibrils with implanted minerals[40]. The final 
and smallest scale is the sub-nanostructure, which covers 
the range from 500 nm and below. This size range covers 
the molecular structure of the indiv idual elements, such as 
collagen molecules, bone mineral crystals and the 
non-collagen organic proteins[41]. 
Bone is a natural two phase organic-inorganic ceramic 
composite consisting of collagen fibrils with  embedded 
well-o rdered inorganic nano-crystalline component. The 
primary organic phase of the bone matrix is Type I co llagen 
and is secreted by osteoblast cells, which in turn forms 
self-assembled collagen fibrils. The fibrils are bundled 
together and predominately self orientate themselves 
parallel to the load-bearing axis of the bone. During the self 
assembly p rocess the collagen fib rils, which  are typically 
300 nm long, develop a 67 nm periodic pattern in which  a 
40 nm gap or hole is formed between the ends of the fibrils 
while a 27 nm overlap results from the bundle behind[43]. 
This pattern creates discrete and discontinuous sites for the 
deposition of plate-like hydroxyapatite (HAP) crystals of 
bone, which form the second phase of the matrix. HAP is a 
mineral composed of calcium phosphate which has the 
general chemical formula of[Ca10(OH)2 (PO4)6]. It is the 
main inorganic component of natural bone, accounting for 
up to about 65% by weight of cortical bone and in  teeth it 
accounts for 97 % by weight of dental enamel in 
mammalian  hard t issue[44]. The d iscontinuous discrete 
sites limit the growth of the crystals and force the crystals to 
grow with a specific crystalline orientation, which is 
parallel to the load-bearing axis of the bone and collagen 
fibrils. The crystal plates typically  have a length of 50 nm, a 
width of around 25 nm and on average a thickness of 3 
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nm[45-48]. The hydroxyapatite has also trace amounts of 
potassium, manganese, sodium, ch lorine, hydrogen 
phosphate, citrate and carbonate[49]. The final component 
of the bone composite consists of the non-collagen organic 
proteins such as the phosphoprotein group, which are 
believed to regulate the formation of the inorganic crystal 
phase by influencing the size, orientation and the 
depositional environment within the spaces between the 
collagen fibrils. Th is organic phase is also believed to be a 
source of calcium and phosphate ions, which are later used 
in the format ion of the mineral phase[50]. 
The combination of the organic and inorganic phases of 
the composite bone structure perform together to give bone 
its unique mechanical properties. Properties such as elastic 
modulus, toughness, strength, stiffness, and fracture 
properties of this complex composite structure gives bone 
and the skeletal system in general its remarkab le ab ility to 
withstand the various mechanical and structural loads 
encountered during normal and extreme physical 
activity[51]. Typical mechanical and physical properties of 
bone are presented in Table 1 along with other 
biocompatible materials that are currently  being used or 
under investigation. When an implant is used within the 
skeletal structure for load bearing applications, its 
mechanical properties should be as close as possible to 
those of natural bone, since both will be exposed to the 
same external loads. If there are significant differences in 
the mechanical properties, with the implant having the 
greater loading bearing capacity, the resulting mechanical 
mis match produces a much lower stress distribution in the 
surrounding bone. The lower stress or stress shielding, 
results in necrosis of the surrounding bone tissue, which 
ultimately leads to implant failure[52, 53]. Th is is why it is 
very important that the biomaterial used for the implant 
should have sufficient strength to withstand the stress 
created by the load, have sufficient stiffness to resist the 
effects of deformat ion without failure and have its 
mechanical properties match the surrounding bone 
tissue[54]. The type of stress the implant will experience is 
dependent on the application of the load. The loads that can 
be encountered singularly or in combinations are tensile, 
compressive, shearing, and tensional. 
 
Figure 1.  Hierarchical structure of bone represented by different levels of organization from Bonzani et al.,[42] 
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Table 1.  Some typical mechanical properties of bone tissue and a selection of several  biocompatible materials[58-64] 
Tissue/Material 
Density 
 
(g cm-3) 
Compressive 
Strength 
(MPa) 
Tensile 
Strength 
(MPa) 
Elastic 
Modulus 
(GPa) 
Natural Materials 
Arterial wall 
Collagen 
Collagen(Rat tail tendon) 
Cancellous bone 
Cortical bone 
 
- 
- 
- 
1.0 – 1.4 
1.8 – 2.0 
 
- 
- 
- 
1.5 – 9.3 
160 Trans. 
240 Long. 
 
0.50 -1.72 
60 
- 
1.5 – 38 
35 Trans. 
283 Long. 
 
0.001 
1.0 
3.75 – 11.5 
0.01 – 1.57 
5 - 23 
 
Magnesium Alloys 
Pure magnesium 
AZ31 (Extruded) 
AZ91D (Die cast) 
 
1.74 
1.78 
1.81 
 
20 - 115 
83 - 97 
160 
 
90 - 190 
241 - 260 
230 
 
45 
45 
45 
Other metal alloys 
Cobalt-Chrome Alloys 
Stainless Steel 
Titanium Alloys 
 
7.8 
7.9 
4.4 
 
- 
- 
- 
 
450 - 960 
480 – 620 
550 – 985 
 
195 - 230 
193 – 200 
100 – 125 
Ceramics 
Synthetic- Hydroxyapatite 
Alumina Ceramics 
(Al2O3 80% - 99%) 
 
3.05 – 3.15 
 
3.30 – 3.99 
 
100 - 900 
 
2000 – 4000 
 
40 – 200 
 
- 
 
70 – 120 
 
260 – 410 
Polymers 
Polymethylmethacrylate 
(PMMA) 
Polyethylene- terephthalate 
(PET) 
 
 
1.12 – 1.20 
 
1.31 – 1.38 
 
 
45 – 107 
 
65 – 90 
 
 
38 – 80 
 
42 – 80 
 
 
1.8 – 3.3 
 
2.2 – 3.5 
 
2.3. Bone Replacement Therapies 
Since the dawn of humanity, the organs and bones of the 
body have been subjected to a variety of medical 
complications such as damage, wear, d isease or just the 
normal ag ing process. Unfortunately, there are times when 
the natural healing processes of the human body are unable 
to effectively repair and heal the damage or disease to the 
organs and bones. It is under these circumstances that 
medical intervention is required to correct or alleviate the 
problem with a suitable procedure that returns functionality 
and removes the pain associated with damage. Historically, 
the demand fo r b iomaterials started with the Egyptians over 
4000 years ago with the use of elephant’s tusks to 
manufacture art ificial legs and teeth. Since then many 
civilizat ions such as the ancient Chinese, Indians, Greeks, 
Romans and Aztec’s have used gold for dentistry, gold 
wires for repairing fractures, glass for artificial eyes and 
wood for artificial legs and teeth[55-57]. Today, medicine 
has been able to extend the average life expectancy in many 
countries and in turn has increased the average lifespan of 
the population. One significant problem that has arisen from 
the aging population is the need fo r suitable bone 
replacement therapies. These bone replacement procedures 
can range from bone grafts needed to fill bone cavities 
resulting from infections and tumours resulting from 
disease, reconstructive surgery to repair bone damage 
resulting from accidents or total joint replacements to 
restore a patient’s mobility after their own joint has failed 
due to disease, injury or wear. 
2.3.1. Bone Transplantation 
Apart from b lood, bone is the most frequently 
transplanted tissue. Historically the preferred bone 
replacement procedure involved the use of autologous bone 
tissue (autograft), since it displays both excellent 
biocompatibility and osteogenic properties. The use of 
autograft’s is well established with good clinical results, 
which makes this procedure the gold standard for bone 
transplantation. There are basically  two types of bone 
transplant procedure carried out; the first is small fragment, 
in which the fragments are used to induce osteogenesis. The 
second uses larger bone fragments, which are used to 
compensate for the large bone loss produced by the removal 
of tumours, bone cysts and traumas[65]. Every year, 
hundreds of thousands of people worldwide require a bone 
transplant[66, 67]. But problems such as donor site 
morb idity and limited supply sources have led researchers 
to investigate alternative sources of bone material. Bone 
tissue can be sourced from a suitable donor of the same 
species, which is called an allograft or it can be sourced 
from another species, xenograft. Medical procedures that 
uses xenogenic and  allogenic bone grafts generally  result in 
a significant response from the body’s immune system. In 
addition, there are also problems associated with the 
possible transmission of pathogens to the donor from the 
graft that needs to be addressed. In addition, obtaining  bone 
tissue for an allograft and/or a xenograft is complicated, 
(medically, ethically and legally) and the grafts are 
expensive to process for human use. Because of these 
concerns there has been a great deal of interest in using 
man-made materials commonly called biomaterials for use 
in bone tissue engineering applications. 
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3. Biomaterials as Bone Substitutes 
An alternative to using natural bone grafts is to use a 
biocompatible synthetic material that possesses unique 
properties that can affectively replace bone tissue. 
To do this the material needs be biologically compatible, 
i.e. it should be nontoxic to the body tissues, 
non-immunogenic and should be chemically stable at body 
temperature and pH[68]. Other important properties include 
a high surface area for maximum cell coverage; the surface 
chemistry should maximize cell and tissue adhesion, 
support the transfer of body fluids and promote vascular 
activity, the material should be cable of being sterilized to 
remove any contamination. And finally the material should 
also be mechanical strong enough to withstand normal 
physical loading encountered in vivo[69, 70]. Biomaterials 
can be classified into four main groups; metals, polymers, 
ceramics and composites. A short discussion of each is 
presented below for completeness, before a detailed 
discussion of nanometre sized hydroxyapatite (nano-HAP) 
in section 5, which is the focus of this research. 
3.1. Metals and Metal Alloys  
Metallic materials such as stainless steel, 
cobalt-chromium based alloys (Co-Cr), t itanium (Ti) and its 
alloys have been widely used for decades to replace failed 
hard tissues. The high elastic modulus and yield strength, 
coupled with good ductility and fracture toughness makes 
metallic materials the ideal choice fo r high load bearing 
applications[71]. Because of these superior mechanical 
properties metal alloys have been used to manufacture total 
hip joints, bone plates, dental components, pins, screws and 
a variety of load bearing implants. Unfortunately, the elastic 
modulus and strength of metallic implants is much higher 
than that of natural bone tissue. Depending on the metal 
alloy used the elastic modulus maybe as much as 10 times 
greater than that of bone in the case of Co-Cr alloys and as 
much as 5 times for Ti alloys[72]. The mis match between 
the mechanical propert ies of the implant and the 
surrounding bone tissue results in stress shielding, which in 
turn produces bone resorption and implant failure. In 
addition, because metallic materials are bio-inert, they do 
not biologically or chemically interact with the surrounding 
tissues and as a result there is very little interfacial bonding 
or osteointegration taking place[73]. One technique 
currently being used to improve the osteointegration of 
metallic  implants is to coat it  with a bioactive material such 
as HAP. 
The main d isadvantages of metallic  implants are; they are 
difficult  to manufacture, are heavier than bone and they 
tend to suffer the effects of corrosion induced by the 
chemical environment of the body flu ids. Furthermore, the 
corrosion bi-products of the metallic implants are toxic and 
induce an immune response. This is why the current 
generation of metallic  implants are being manufactured 
from Ti alloys; they have a low elastic modulus and have a 
higher resistance to corrosion than conventional stainless 
steel and Co-Cr alloys[74]. In addition, Ti can be anodized 
to produce a porous oxide layer that can be used directly to 
improve integration with the surrounding tissues or be used 
as an anchoring structure for a coating of bioactive material 
that can integrate with the surrounding tissues[75, 76]. 
3.2. Polymers 
The application of b iomaterials in tissue engineering for 
tissue repair and regeneration has generally favoured 
bio-inert  materials for permanent bio-implants such as 
hip-replacements. And in the case of scaffolding materials, 
both natural and synthetic polymers have been investigated. 
Polymers are long chain molecules composed of repeated 
small simple chemical monomer units. Polymers have low 
densities, are flexib le, resilient and are surface modifiab le 
which makes them suitable for a variety of applications[77]. 
Typical applications of polymers are tissue scaffolds, skin 
augmentation, breast implants, denture bases, hip joints, 
blood vessels, cartilage replacement, sutures, bone screws, 
pins, plates and drug delivery devices[78]. 
The operational demands placed on polymeric materials 
used in tissue scaffolds or implants are numerous and there 
are many challenges to overcome to achieve successful 
clin ical outcome. For example, biocompatibility is crucial 
in preventing any cytotoxicity, immunological reactions and 
inflammat ion responses from the body[79-81]. In addit ion, 
the scaffolding material must be able to cope with the 
mechanical stresses resulting from the growth stages as well 
as prevent any rapid bulk degradation crating voids. The 
material must also be easily sterilised prior to application 
without any significant changes to its surface chemistry 
[82-84]. At the molecu lar level, this is extremely important 
as the surface’s topography and chemistry are key factors in 
gaining the correct response from the cells, which will in 
return promote cell adhesion and proliferat ion [85-88]. The 
findings of Andersson et al suggests that in the case of 
epithelial cell attachment to surfaces of similar chemistry, 
the morphology and cytokine production are strongly 
dependent on the underlying nanometre sized topography 
[89]. 
Polymeric materials can be manufactured from many 
natural sources or from synthetic materials. Natural 
biodegradable materials have been extensively investigated 
for use in t issue engineering since the body’s natural 
pathways can easily handle the breakdown of their 
metabolic by-products. Natural polymers such as 
polysaccharides[90-94], chitosan[95-99], hyaluronic based 
derivatives[100-103] and protein-based materials such as 
fibrin gel[104, 105] and collagen[106, 107], have shown 
favourable outcomes. On the other hand, synthetic 
biodegradable polymers have been fabricated under 
controlled conditions to produce scaffolds with tuneable, 
predictable mechanical and physical properties. And being 
based on simple h igh purity constituent monomers, these 
biopolymers have lower toxicity reactions with the body 
and their degradation rate can easily be controlled. 
Examples of bulk b iodegradable polymers include Po ly 
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(lactic acid), PLA[108-113], Po ly (L-lact ic acid ), PLLA 
[114-117], Poly (lact ic-co-glycolic acid), PLGA[118-121], 
Poly-caprolactone PCL[122-125] and Po ly (g lycolic acid), 
PGA[126-129]. These are generally poly-α-hydrox esters 
that de-esterifies in the body as the polymer degrades to 
simple metabolites[130]. Currently available biodegradable 
sutures in clinical use are made from PLA and PGA. These 
synthetic polymers can also be made into different shapes 
and structures, such as pellets, disks, films and fibres as 
required for the specific application. 
Due to the fact that the extracellular matrix (ECM) has a 
fibrous nature and has features at the nanometre scale or sub 
micron level, engineering materials mimicking the ECM is 
the ultimate goal of many research teams worldwide. Two 
recent developments in nanotechnology, has been the 
refinement of electro-spinning and phase separation 
techniques to produce polymeric nanoscaffolds[131-134]. 
Initially developed by the text ile  industry, electro-spinning 
has been used for the past 100 years. Refinements in the 
past decade have seen this technique being used 
increasingly in  the manufacture of nanometre sized fibrous 
polymer scaffo lds. Membranes of PLA and PLGA, fibro in 
and collagen have been made using this technique. As 
shown by Agarwal et al[135], this technique is favourable 
and conducive for cells attaching and pro liferat ing onto this 
material. Th is nano-fibrous electro-spun material can be 
further bioengineered to resemble the ECM at the 
nanometre scale level by coating the material with collagen 
macromolecules. This technique is still evolving and there 
are still challenges ahead. Other nano-polymeric substrates 
have been manufactured using phase separation techniques 
that produce a film of the desired polymer. Recent 
developments to this technique have produced nanometre- 
sized features over its surface to enhance the value of this 
material[136-138]. The studies by Ma have shown that 
nano-polymers by this technique have an advantage in 
terms of surface area and enhanced 3D connectivity for 
tissue engineering[139]. Furthermore, polymeric materials 
are effective biocompatible materials that have also been 
extensively investigated for the controlled delivery of drugs 
to specific organs within the body[140-142]. 
Although polymers have been effectively used in a 
number of tissue engineering applications, polymers have a 
lower mechanical strength compared to metals and ceramics, 
so they are generally used predominantly in low load 
bearing applicat ions such as soft tissue engineering. In 
addition there are still issues to be resolved like local 
inflammat ion resulting from the degradation products and 
the uneven bio scaffold degradation, which can  disrupt the 
gradual integration of the surrounding tissues. Because of 
this, alternate scaffold and implant materials are currently 
under investigation. For example, recent studies using 
bioactive glass as a scaffold; revealed that when the glass 
was seeded with osteoblasts, a positive effect could be seen 
in cell pro liferat ion[143]. 
3.3. Biological Ceramics 
Ceramics are non-metallic and inorganic materials that 
are used in hard tissue engineering applications where they 
are collect ively termed as biological ceramics or 
bioceramics. The advantages of using bioceramics are; they 
are physically strong, both chemically and thermally stable, 
provide good wear resistance and are durable[144]. In 
addition, these materials are readily available, can be 
shaped to suit the application, they are also biocompatible, 
hemocompatible, nontoxic, non-immunogenic and can be 
easily sterilised[145]. The only d isadvantages of using 
bioceramics are, they tend to be brittle, have low fracture 
toughness and are not resilient. But they have found 
application in hip  jo ints, coatings on implants, maxillofacial 
reconstruction, bone tissue engineering and drug delivery 
devices. 
Bioceramics can be categorized into four types, which 
are dependent upon the tissue response they solicit. The first 
type is bio-inert ceramics, (i.e. alumina and zirconia) which 
are generally used in dental implants and orthopaedics 
[146,147]. These materials do not biologically or 
chemically interact with the surrounding tissues; hence they 
don’t solicit a noticeable response from the t issues. The 
second category is bioactive (i.e. bioactive g lasses, 
hydroxyapatite and glass ceramics), these materials interact 
with the surrounding tissues and induce a strong 
osteointegrative response[148]. A typical applicat ion of 
these materials is the coating of titanium alloy implants to 
improve their osteointegration with the surrounding tissues 
[149]. The third type is resorbable ceramics, (i.e. t ricalcium 
phosphate (TCP)) in this case the TCP forms a scaffold 
structure for new bone cells to adhere to and proliferate 
[150,151]. During this process the new bone tissues 
continue to grow and rep lace the scaffo ld structure as it  is 
slowly resorbed[152]. And the final type is porous; this type 
of bioceramic permits the surrounding host tissues to 
penetrate into the pores of the implant (HAP coated metal 
and alumina implants). Because of the attractive features 
and properties of bioceramics there has been a significant 
effort into researching and developing new synthetic 
biomaterials such as porous coralline, calcium sulphates, 
and calcium phosphates, i.e. HAP[153-155]. The 
importance of calcium phosphates as bioceramics is 
discussed in detail in section 4 and particular attention is 
paid to HAP in section 5, a  member of the calcium 
phosphate family and the focus of this review. 
3.4. Composites 
A composite material consists of two or more distinct 
parts or phases[156]. The major advantage of using 
composite biomaterials stems from the fact a single phase 
material may not have all the required properties for a 
particular applicat ion[157]. However, by combining this 
phase with one or more other phases with differing physical 
and chemical properties it is possible to create a composite 
material with superior propert ies to those of the indiv idual 
components. A good example is bone, which  is a  composite 
of Type 1 co llagen and HAP, and an example of a manmade 
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composite is coating a titanium implant with a bioactive 
material such as HAP or b ioactive glass to promote bone 
attachment[158]. Similar composites have been developed 
to produce biomaterials for hard t issue engineering 
applications that have used a 2 phase HAP-polymer mixture 
to produce a composite with a modulus of elasticity close to 
natural bone[159]. 
4. Calcium Phosphates Ceramics 
The inorganic phase of bone is composed of a calcium 
phosphate (CaP) compound, namely, HAP which forms 
crystal platelets, a description of which was presented in 
section 2.2. (Bone: Its hierarchical structure). CaP 
compounds exist in several phases which can be 
discriminated by the stoichiometric ratio of calcium to 
phosphate (Ca:P) which is important for crystallin ity, 
solubility and strength[160]. There are numerous Ca:P 
compounds, each with their own unique crystalline structure 
and Ca:P ratio, which means that they have different 
properties and form under different conditions[161]. For 
example, the stability of CaP compounds is influenced by 
controlling the Ca:P ratio, water p resent, formation 
temperature and pH[162]. The Ca:P ratio varies from 0.5 to 
2.0, see Table 2, however, for rat ios below 1, the solubility 
rates and the acidity are both high making these CaP 
compounds unsuitable for biomedical applications. Several 
members of CaP family  have been used in a variety of 
tissue engineering applications to date. In addition, CaP 
compounds have been combined with collagen, to form 
composite biomaterials that display some similarity to 
natural bone tissue[163]. 
Amorphous calcium phosphate (ACP) is the least stable 
solid phase of the CaP family formed in solution[164]. It is 
usually the first phase formed by precipitation in solutions 
containing high concentrations of calcium and phosphate. 
ACP has a Ca:P ratio of around 1.5, generally has spherical 
morphology and lacks any internal crystalline structure 
normally  associated with CaP compounds[165]. It  is usually 
considered the precursor crystalline CaP compounds, since 
heating can convert ACP to poorly  crystalline apatite at 
600℃ , tri-calcium phosphate (TCP) at 800℃  and HAP 
around 800℃  respectively[166]. ACP has been used in 
mineral releasing composites for dental fillings, bone 
cements and for non-load bearing implants in bone tissue 
engineering[167]. 
However, the two most prominent calcium phosphate 
bioceramics currently being used in a variety of medical 
procedures are TCP and HAP. Both materials are 
biocompatible, osteconductive and directly bond with 
natural bone[168, 169]. TCP is a polymorph material with 
two distinct phases (α-TCP and β-TCP) each phase is 
formed by varying the humidity and the sintering 
temperature. The α phase is formed in dry heat with 
temperatures above 1300℃  then quenching in water, while 
the β phase is produced in a humid atmosphere during the 
sintering process[166]. There are also significant 
differences in the propert ies, for example β-TCP is less 
soluble and less reactive than α-TCP which is unstable in 
water and reacts to produce HAP. A major advantage of 
using β-TCP in vivo is that its solubility, dissolution and 
re-precip itation results in a gradual phase change into 
carbonated apatite. The resorption of the carbonated apatite 
by the macrophages, giant cells and osteclasts allows the 
β-TCP to be gradually  replaced by natural mineralized  bone 
tissue. Both α-TCP and β-TCP have been used in  bone 
tissue engineering applications; α-TCP is mainly used in 
some CaP cements while β-TCP has been used in bone 
cements and fillers, low load bearing implants, used to 
provide a degradable coating on metallic  implants to induce 
a favourable biological response and increase 
oseointegration of the implant[170, 171]. 
Table 2.  A selection of common calcium phosphate compounds,[172, 173] 
Ca: P 
ratio Chemical formula Compound 
pH stability range 
in aqueous 
solutions at 25ºC 
Solubility 
at 25ºC 
(g/L) 
Solubility 
at 25ºC 
-log(Ks) 
0.5 Ca(H2PO4)2.H2O 
Mono calcium phosphate  mono hydrate 
(MCPM) 0.0 – 2.0 18 1.14 
1.0 CaHPO4.2H2O Di-calcium phosphate Di-hydrate (DCPD) 2.0 – 6.0 0.09 6.59 
1.5 α-Ca3(PO4)2 
α-Tricalcium phosphate 
(α-TCP) * ~0.0025 25.5 
1.5 β-Ca3(PO4)2 β-Tricalcium phosphate (β-TCP) * ~0.0005 28.9 
1.67 Ca10(PO4)6(OH)2 Hydroxyapatite (HAP) 9.5 – 12 ~0.0003 116.8 
* Compound cannot be precipitated from an aqueous solution 
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5. Hydroxyapatite and Nanometre Scale 
Hydroxyapatite 
5.1. Hydroxyapatite  
Due to the close chemical similarity of synthetic HAP to 
the natural inorganic bone matrix component, there has 
been an extensive research effort to employ synthetic HAP 
as a bone substitute or replacement in several clinical 
procedures[174, 175]. There are four main of advantages of 
using synthetic HAP; firstly, it has good biocompatib ility to 
surrounding body tissues, secondly its biodegradability in 
situ is slow, thirdly it provides good osteoconductivity and 
finally it has good osteoinductivity capabilit ies[176-179]. 
An investigation by Taniguchi et al[180] revealed that 
sintered HAP provided a good biocompatible response to 
soft tissues such as skin, muscle and gums. It is this 
favourable tissue response that makes synthetic HAP an 
ideal candidate for orthopaedic and dental implants. This is 
the reason why synthetic HAP has been widely used for a 
variety of hard tissues applications such as; bone repair, 
bone augmentation, the coating of metal implants and used 
as a filling material in both bone and teeth[181,182]. 
Despite its many advantages, pure HAP has unfortunately 
very poor mechanical strength. As a result, pure HAP 
ceramics are restricted to low load-bearing applicat ions. 
However in  some cases, combining HAP with other 
materials such as polymers and/or glass to form a composite 
material can alleviate these inherently low mechanical 
properties. For example materials such as high-density 
polyethylene (PE) and polypropylene have been 
successfully used to improve the load bearing capabilit ies of 
HAP[183, 184].  
Another significant advantage of using HAP as a 
component of a composite material is that its complex 
structure provides a good absorption matrix for other 
molecules. The absorption properties of HAP have been 
exploited fo r a number o f in situ applications, such as 
HAP-antib iotic and HAP-drug composites for slow 
release[186-188]. These composites have also proved to be 
effective in the treatment of diseases such as osteomyelitis, 
where the slow drug release has resulted in a successful 
recovery from the disease[189]. 
 
Figure 2.  The unit cell of hydroxyapatite in P63/m space group[185] 
5.2. Nanometre Scale Hydroxyapati te 
Research to date in both nanoscience and nanotechnology 
has highlighted the need to investigate the formation of 
HAP in the nanometre size range and to clearly define the 
properties of HAP at this scale. This is very important in 
nanotechnology because different forms of a material at the 
nanometre scale can result in significant differences in its 
physicochemical properties[190-193]. Parameters such as 
the structure of the HAP and how it is processed can 
influence the properties. For example when the parameters 
are adjusted it is possible to change the particle shape of the 
HAP being produced. This means that it is possible to 
produce rods, tubes, plates and spheres[46, 194-196]. Major 
improvements in the properties of HAP can be achieved 
when the material is synthesised in the nanometre scale 
[197-200]. 
The improved properties of the HAP can  also have a 
significant effect in interacting with surrounding body 
tissues[201, 202]. For example, in a HAP particle study 
conducted by Sun et al[197], the influence of particle size 
on in vivo osteoblast cells found that the inflammatory 
response was inhibited when smaller part icles sizes (0.5 – 
3.0 µm) were used. Furthermore, Hu et al was able to 
demonstrate that nano-HAP particles used in their study 
displayed a strong anti-tumour effect, and in part icular the 
nano-HAP particles were ab le to inhibit  the growth of 
hepatic tumour cells[203]. In a similar study, Li et al were 
able to demonstrate the beneficial effect of a 
nano-composite material composed of HAP and chitosan on 
human gastric cancer cells[204]. Similar studies have also 
looked using nano-HAP as a delivery platform for the slow 
release of drugs and gene therapies for the treatment of 
tumours[205, 206]. In a comparable study using nano-HAP 
impregnated with an antibacterial or antifungal material, it 
was possible to effectively inhibit  the growth and 
proliferation of infect ious microorganisms[207]. 
Bioceramics composed of nano-HAP are currently  being 
researched and in some cases used in a variety of medical 
procedures other than drug delivery. For example, 
nano-HAP has been extensively used in a range of bone 
cements and fillers which are used to provide a scaffold 
structure that encourages the growth of natural bone 
forming tissue and form an effective alternative to bone 
grafts in a number o f procedures[208]. Currently many 
orthopaedic implants are based on metallic materials such 
as stainless steel and titanium alloys[209]; unfortunately 
these materials are bio-inert and do not interact or form 
direct bonds with the surrounding bone tissue. The use of 
nano-HAP has opened new opportunities in designing 
biocompatible coatings for metallic implants. For example, 
the use of plasma spraying techniques to create thin 
coatings that can deliver controlled thicknesses of 
nano-HAP that can create an effective environment for 
osteoconduction, protein adhesion and bone in growth[210]. 
Another interesting feature of using nano-HAP as a scaffold 
is that it can be pre-treated to produce micrometer sized 
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cracks to simulate the cracks naturally found in bone tissue 
that results from repetit ive stress injuries such as running or 
repeated lifting of heavy loads. As in the case of natural 
bone, the cracks in the nano-HAP can promote bone 
re-growth[211]. 
The advantage of using nano-HAP lies in  its ability to 
integrate with bone tissue, promote and support bone in 
growth. In fact, one interesting property of nano-HAP is 
that when it bonds with bone, it fo rms an indistinguishable 
union with the surrounding bone tissue. Unfortunately, 
there are some disadvantages of using nano-HAP; they 
range from the in itial synthesis process, where the 
composition of the final product can be greatly affected by 
even small changes in the init ial reaction conditions such as 
pH and formation temperature. Furthermore, nano-HAP 
cannot be used in bulk form to a make a load bearing 
orthopaedic implant because the HAP has low mechanical 
properties such as strength and fracture toughness. Also the 
solubility and bioactivity o f nano-HAP is influenced by its 
phase purity, ionic purity and its crystalline structure.  
To overcome the d isadvantages in the properties of pure 
nano-HAP, in particular its mechanical strength, composite 
materials composed primarily of nano-HAP combined with 
a variety of other materials with desirable properties have 
been investigated. For example, organic materials such as 
collagen, gelat ine, chitosan and poly (lactic acid) (PLA) 
have been used to reinforce the nano-HAP matrix, in  a 
similar way collagen does in the natural bone matrix, and 
significantly improve the mechanical p roperties[212-216]. 
Also adding nano-HAP into a polymer matrix has been 
found to turn a non-bioactive polymer into a bone bonding 
composite with improved mechanical properties such as 
elastic modulus and hardness[215]. The possibility of 
making a nano-HAP composite as strong as cortical bone 
with  good biocompatibility, slow b iodegradability  in situ, 
and osteoconductivity and osteoinductivity capabilities by 
adding an extra reinforcing phase or phases makes the 
composite a very attractive alternative[213]. 
5.3. Synthesis of Nanometre Size Hydroxyapatite  
Traditionally, several procedures have been developed 
and used to produce HAP and calcium phosphate ceramics. 
These diverse procedures include homogeneous precipitati
on[217, 218], sol-gel[219, 220], spray dry method[221], 
plasma spray[222], hydrothermal[223, 224], reverse micelle 
[225] and ultrasonic spray freeze drying processes[226]. Of 
these the sol-gel is the most appealing method since it  is 
based on a wet chemical technique that has a simple and 
straight forward p rocedure that can economically  produce 
HAP without rely ing on expensive specialised equipment. 
Furthermore, this technique can be scaled up to meet high 
demands. However; the main problem in using this 
technique is being able to effectively fine-tune, with in a 
small parameter range, the size and morphology of the 
nano-particles produced. This fine-tuning of the size and 
morphology is crucial in determining the properties of the 
resulting ultrafine nano-HAP powders. 
Crystalline materials can be produced from solutions, 
using wet chemical techniques, but a subsequent thermal 
treatment at elevated temperatures is required to produce 
the specific crystalline phases. Both the particle size and 
morphology of HAP produced using this technique can be 
efficiently  controlled by vary ing the experimental 
parameters that regulate the nucleation, the aging p rocess 
and the growth kinetics of the forming particles. The 
parameters that control the production of mono phase HAP 
are the initial reactants, the preparation temperature and the 
pH value. Both Khopade et.al[227] and An et.al[228];  using 
a wet chemical method were able to produced HAP 
particles that with a plate like structure or morphology. This 
structure is in complete contrast to the spherical-shaped 
HAP part icles that are normally synthesized when 
ultrasonic irradiation is used during the processing stage. 
The most commonly used wet chemical technique is the 
precipitation method and it can be used to produce 
homogeneous or inhomogeneous calcium phosphate 
ceramics[229]. It is important to note that variables such as 
Ca:P ratios, structural defects, crystal size, temperature and 
the preparation procedures can have a significant impact on 
the electronic properties of the manufactured HAP[230]. A 
number of chemical routes have been used to manufacture 
HAP; each p roducing a significant variation from the 
normal HAP phase, and this clearly demonstrates that the 
HAP produced is procedure dependent[231]. Furthermore, 
different HAP phases can be produced by the influence of 
other molecules present in the manufacturing process. 
Wang et al successfully studied the in fluence of other 
molecules as molecular templates, for producing nanometre 
sized HAP rods[232].  
Guo and Xiao studied the properties of nano-crystalline 
HAP produced during a hydrothermal process and their 
investigation revealed that the particle size decreased when 
the thermal treatment temperature increased[233]. In  a 
similar investigation by Meissner et al. found that both size 
and morphology of the produced HAP could be controlled, 
both particle size and morphology were dependent on the 
precipitation temperature and the ultrasonic power 
used[234]. The part icle size and temperature relationship 
has also been investigated by Laquerriere et al who were 
able to demonstrate that increasing thermal treatment 
temperatures produced a decreasing particle size[235]. In 
addition, Li-Yun et al confirmed the dependence of the 
particle’s size and morphology under ultrasonic irradiat ion, 
as they prepared a mono-phase nano-HAP material using a 
300W ultrasonic transducer[236]. 
An important procedure carried out during sample 
preparation is wet milling. Ultrasonic irradiation is used 
during the wet milling procedure as an efficient means of 
dispersing and de-agglomerat ing the sample part icles during 
the grinding process. The sonochemical effect, which 
produces acoustic cavitations, also promotes both chemical 
reactions and physical effects that directly influence the 
particle morphology during the growth phase. There are a 
number of advantages in using ultrasonic irradiation during 
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the manufacture of superfine part icle slurries. The first is 
the increased reaction speed, secondly there is a significant 
reduction in processing time and thirdly  there is an overall 
improvement in the efficient use of energy during the 
process operation[237, 238]. Preliminary  work in this thesis 
research used a number of chemical precipitation 
techniques, during which several reactants were 
investigated. The subsequent results found that each 
reactant had varying degrees of success in controlling the 
particle size and morphology. Out of this work a new 
chemical route was developed that used calcium n itrate tetra 
hydrate[Ca (NO3)2.4H2O] and potassium dihydrogen 
phosphate[KH2PO4] as the main  reactant materials. These 
reactants greatly improved the control of both particle size 
and morphology. The pH was regulated during the synthesis 
process by the addition of ammonium hydroxide 
[NH4OH][239]. Once the nano-HAP powder had been 
manufactured and dried, it was then used in its present form 
for advanced characterization or alternatively compacted in 
a hydraulic press to produce a variety of coupon sizes and 
shapes. The coupons were then sintered in a furnace at 
temperatures below the melt ing point, to fuse the crystals 
into a ceramic structure. 
5.4. Properties of Porous Nano Hydroxyapatite  
Ceramics 
5.4.1. Porosity and Permeability 
The porosity, or storage capacity, of porous HAP can be 
defined as the percentage of space in a material not 
occupied by the ceramic matrix, usually called the 
volumetric porosity. In  the case of cortical bone the pore 
size ranges from 1 to 100 µm with typical volumetric 
porosities ranging from 5 to 10%[240]. HAP ceramics with 
low volumetric viscosities generally have high mechanical 
properties but provide only limited opportunities for cell 
and tissue in growth. Porous HAP ceramics have the 
potential to p rovide a good biological environment to 
promote cell adhesion, cellu lar interactions, proliferat ion, 
and migrat ion. The downside to the increase in porosity is 
the decrease in mechanical properties, such as strength, 
stiffness and elastic modulus. Both the cellular response and 
the mechanical properties are dependent upon the pore size, 
porosity, interconnecting porosity and pore distribution. The 
American Society for Testing Materials (ASTM) has 
defined porous materials into three classificat ions, 
interconnecting (open pores), non-connecting (closed pores), 
or a combination of both[241]. The interconnecting porosity 
within  the matrix scaffold is a very important property since 
it permits fluid flow through the porous ceramic material. 
The effectiveness of the fluid flow through this natural 
plumbing system is called the permeability. 
Pore sizes smaller than 10 µm define a micro-porous 
structure in the ceramic. The size of these micro -pores 
usually prevents the influx of cells into the pore structure, 
but fluids are still ab le to penetrate into and flow through 
the scaffold structure. When the pore size is greater than 10 
µm they are classified as macro-pores and are large enough 
for both cells and fluids to enter the pore structure. The 
macro-pores have a large pore surface area to bulk vo lume 
ratio which actively promotes cell adhesion, cellular 
interactions, proliferat ion, and migration. Using techniques 
that can assist in forming a porous structure within the 
ceramic has many advantages, since the architecture of the 
porous structure can be controlled efficiently. The ability to 
select the pore size, pore geometry and the interconnecting 
porosity allows cell and tissue growth throughout the 
porous scaffold structure. For example bone forming cells 
grow far more efficiently when they are attached to a 
substrate rather than being suspended in a culture medium. 
In fact the ability of bone to bond with HAP is a major 
reason why many researchers have studied and continue to 
investigate this ceramic for b iomedical applicat ions[242].  
When the pores are large and open, the HAP matrix is 
usually formed into a strut like structure, which forms the 
pore walls. The resulting interconnecting open face pore 
structure produces a network of struts that form flow 
channels throughout the matrix. The pore channels are 
conducive for cell and tissue colonisation. In addition the 
pore channels provide high permeability flows for the cells 
to be supplied with nutrients and for the removal of 
metabolic waste products from natural cell’s activity[243]. 
This type of pore structure is ideal for cells and tissue 
growth, but it has poor mechanical p roperties. On the other 
hand, if the pores are closed, the HAP matrix forms a 
network of interconnecting plate like structures that produce 
a high-density solid. This configuration p revents the 
passage of fluids or cells to neighbouring pores or the rest 
of the scaffold. Since the arch itecture of the scaffold 
requires a significant amount of porosity to accommodate 
flu id transfer and tissue in growth, an effective balance 
between porosity and the mechanical p roperties must be 
achieved. It simply comes down to the fact that when the 
porosity increases, the mechanical properties of the scaffold 
decrease rapidly. Furthermore, as the porosity increases, 
there is an increase in matrix surface area, which is exposed 
to the environmental effects of erosion, changing surface 
chemistry and cellu lar activity. For example, bioactive 
materials like HAP, exh ibit surface modification with time 
when exposed to bodily fluids and cellular act ivity. So the 
application of high porosity, low strength biomaterials is 
restricted to non-load bearing applications. In th is particular 
application, where the in itial function of the scaffold is not 
load-bearing, then the porous scaffold can prov ide an 
effective functional implant or biomedical device. 
5.4.2. Mechanical Properties 
The architecture of a scaffold  for bone tissue engineering 
requires a significant amount of porosity to accommodate 
flu id transfer and tissue in growth. In addition, the 
mechanical properties of the scaffold must also be closely 
matched with those of natural bone. Therefore, an effective 
balance between porosity and the mechanical properties 
such as strength must be achieved. The fact  is that when the 
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porosity increases, the strength, along with other 
mechanical p roperties rapid ly decreases. Because strength 
is an important property of a load-bearing scaffold, the 
internal architecture of the scaffold structure must be 
carefully considered since it strongly in fluences the ability 
of the scaffold to resist applied loads and perform 
successfully[244]. Therefore, by adjusting the porosity, it is 
possible to fine-tune the strength of a scaffo ld for a 
site-specific applicat ion[245].  
The strength of a bio-ceramic composed of nanometre 
sized HAP powders is dependent on grain size, grain 
distribution, porosity, compression pressure, sintering 
temperature and micro-structural defects resulting from the 
manufacturing p rocess. Hardness testing is frequently used 
to characterise mechanical properties, such as strength, of 
bulk solid samples and thin films. The hardness technique 
involves pressing a hard indenter of well-defined geometry 
into the surface of the sample under a p redetermined 
load[246]. Indentation is considered an attractive method 
for assessing the mechanical properties of materials since it 
is basically  a non-destructive in contrast to other techniques 
such as bending, compression and extension of 
samples[247]. Some typical mechanical properties of a 
synthetic HAP are p resented in Table 1 along with other 
biocompatible materials for comparative purposes. 
Unfortunately, due to its low mechanical strength and brittle 
nature, pure HAP based ceramics are restricted to low load 
bearing clin ical applications[248]. Current and probable 
future directions of research in this field will focus on 
efficiently combin ing nanometre scale HAP with other 
biocompatible materials to produce a composite that 
allev iates the lower mechanical propert ies of pure HAP. 
This is currently an  active area of study with materials such 
as high-density polymers[183, 184], metals and bioactive 
glasses being investigated[249, 250]. 
6. Conclusions 
The consequences of bone traumatisation, loss or damage, 
resulting from in jury or disease can dramatically reduce the 
quality of life for a patient at a significant socioeconomic 
cost. This is further complicated by the non-integration of 
current conventional implants and biomedical devices with 
the surrounding normal tissues. And as a result, revision 
surgery is often required to remove or repair the implant 
device. The aim of bone tissue engineering is not only to 
repair, but also init iate natural bone regeneration. The 
ultimate goal is to develop a synthetic tissue scaffold that 
uses biocompatible materials to produce an effective 
functional replacement for damaged bone tissue. Thus, 
avoiding all the problems associated with current bone 
transplantation procedures. From a materials point of view, 
the intrinsic properties of HAP offer many significant 
advantages to the development of a hard tissue scaffold. 
These favourable properties include good biocompatibility 
and bioactivity, slow in situ biodegradability and good 
which can  osteoconductivity and osteoinductivity 
capabilit ies complement bone remodelling. 
Despite substantial progress in the manufacture of HAP 
and HAP based ceramics, there are still significant 
challenges to overcome. For example, fine tuning of the 
ceramics mechanical properties to match those of natural 
bone will permit uniform d istribution of stresses in situ and 
prevent stress shielding. Future research into improving the 
mechanical performance of HAP ceramics lies in 
investigating potential composites composed of HAP and 
suitable additives that could significantly enhance the 
composites performance and stability in situ. The 
development of these new improved HAP based composites 
would require that their structure and mechanical properties 
be optimized to effectively mimic bone. The challenge will 
be to find suitable biocompatible additives with desirab le 
properties that can be incorporated with the HAP to form a 
composite with superior mechanical propert ies without 
soliciting any unfavourable inflammatory  responses. Recent 
studies of HAP based composites composed with blended 
natural polymers such as chitin; chitosan and collagen have 
shown both improved biocompatibility and mechanical 
properties[251, 252]. For example, Rivera-Munzoz has 
demonstrated that the inclusion of small concentrations of 
gelatine, (typically around 10%) can produce dramat ic 
improvements in the compressive strength[253]. While 
studies by Balani et al. have shown the inclusion of carbon 
nano-tubes (CNT) and Al2O3 into the matrix could 
significantly improve the mechanical properties of the HAP 
composite[254]. And recently, Venkatesan et al. has 
investigated the properties of a CNT-chitosan-HAP 
composite for potential t issue engineering applications[255]. 
The construction of these new HAP based composites could 
also initiate further investigations into the effects of scale 
on the chemical-physical properties at both the nanometre 
and micrometre scales. In addition, surface 
functionalization of the HAP material could also be used to 
incorporate slow release biological active molecules, which 
could promote both cellular activity and bone integration. 
Future studies in bone tissue engineering using a 
combination of the above mentioned techniques have the 
potential to create a more efficient regeneration of 
traumatised, lost or damage skeletal t issue and result in a 
more successful clin ical outcome. 
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